This book is a comprehensive and up-to-date compendium on all aspects of blood and marrow transplantation in children. After an introductory chapter describing the history of pediatric blood and marrow transplantation, subsequent chapters discuss pediatric-specific aspects of transplantation, including stem cell sources suitable for transplantation, preparative regimens, graft-versus-host disease, complications related to transplantation, and late effects. The role of blood and marrow transplantation in various specific pediatric diseases is then examined, and the closing chapter considers future directions. The authors are all internationally recognized experts and offer a largely evidence-based consensus on etiology, biology, and treatment. This handbook has far-reaching applicability to the clinical diagnosis and management of pediatric diseases that are treatable with blood and marrow transplantation and will prove invaluable to specialists, generalists, and trainees alike.

Clinical and pathological observations have unequivocally indicated an increase in the incidence of malignant neoplasia during the last two decades. Despite important advances in surgery, radiotherapy and chemotherapy, mortality from tumours still tends to increase. Cancer research has therefore concentrated not only on early diagnosis and therapy but also, in line with recent trends in medical science, on the prevention of oncogenesis. One effi- cient prophylactic approach is the treatment of preblastomatoses, which include the preneoplastic lesions of the mouth. The most frequent oral pre- cancerosis, leukoplakia, has been studied extensively during the last 20 years with regard to its pathogenesis,clinical course,and response to therapy. In Hungary, studies of oral leukoplakia have a century-long tradition. The term leukoplakia was coined by the Hungarian dermatologist Ern/) Schwimmer who recognized the precancerous nature of the condition and its relationship to tobacco smoking exactly 100 years ago. In the middle of this century another Hungarian scientist, Karoly Balogh established that most leukoplakias have two stages, - reversible and irreversible - and that early lesions may heal spontaneously after the elimination of irritational factors. The incidence of leukoplakia in random population groups was determined for the first time in the world by the Hungarian investigator Pal Bruszt, and reported to be 3.6 %. Subsequent studies in other countries confirmed a range of 0.2-8.1 %, depending on geographical and environ- mental conditions, way of life, and relevant habits.

Leading experts summarize and synthesize the latest discoveries concerning the changes that occur in tumor cells as they develop resistance to anticancer drugs, and suggest new approaches to preventing and overcoming it. The authors review physiological resistance based upon tumor architecture, cellular resistance based on drug transport, epigenetic changes that neutralize or bypass drug cytotoxicity, and genetic changes that alter drug target molecules by decreasing or eliminating drug binding and efficacy. Highlights include new insights into resistance to antiangiogenic therapies, oncogenes and tumor suppressor genes in therapeutic resistance, cancer stem cells, and the development of more effective therapies. There are also new findings on tumor immune escape mechanisms, gene amplification in drug resistance, the molecular determinants of multidrug resistance, and resistance to taxanes and Herceptin.

Lung cancer remains an extremely difficult neoplasm to treat effectively. A large part of our lack of success in dealing with these patients is related to our empiric therapeutic attempts. Slowly our basic understanding of the lung cancers is improving and techniques are becoming available to allow us to better understand the biology of these neoplasms. This volume reviews several areas of interest in regard to the biologic behavior and characteris of lung cancer. tics Chapters deal with the in vitro growth of small cell lung cancer, the inves tigation of growth factors in human lung cancer, the production of mono clonal antibodies against lung cancer and the application and potential use fulness of the human tumor cloning assay in lung cancer management. These avenues of investigation are likely to establish a more scientific basis on which more rational therapy can be designed. Carney and associates have established several continuous small cell lung cancer cell lines in their laboratory. The amine precursor uptake and decar boxylation (APUD) properties of this neoplasm have been confirmed by demonstrating the presence of neurosecretory granules and high levels of the APUD enzyme L-dopa decarboxylase. In addition, several new markers have been documented including bombesin, creatine-kinase BB and neuron specific enolase. These tumor products along with others may be useful serum markers in patients with small cell lung cancer."

This is a comprehensive, state-of-the-art guide to the diagnosis, treatment, and biology of multiple myeloma and related plasma disorders. Edited and written by a multidisciplinary group of recognized authorities from the Mayo Clinic, it presents clear guidelines on diagnosis and therapy and covers all aspects of multiple myeloma, from molecular classification and diagnosis, to risk stratification and therapy. Closely related plasma cell disorders such as solitary plasmacytoma, Waldenstrom macroglobulinemia, and light chain amyloidosis are discussed in detail as well. The book addresses often overlooked topics, including the role of radiation therapy, vertebral augmentation, and supportive care. Our understanding of this group of disorders is developing at an unprecedented rate, and Multiple Myeloma meets the need among oncologists and hematologists for a clear, timely, and authoritative resource on their biology, diagnosis, and treatment.

This book highlights recent progress in the molecular, cellular and immunological mechanisms that contribute to the pathophysiology of cancer and the design of therapeutic modalities based upon these molecular insights. Areas of particular emphasis include cancer immunology and the immunotherapy of cancer, the role of cytokines in modulating the social bahaviour of cancer cells, the genetic alterations that characterize human cancer and metastasis, and a consideration of the more experimental approaches to cancer therapy, including gene therapy using expression vectors for cytokines and their receptors, antisense RNA therapy, and anti-idiotypic antibody immunization. This volume serves to introduce the general reader as well as the cancer specialist to personalized perspectives of particular topics in cancer research by leading research groups in the field. The combination of a ''reviews''-approach with a more research-oriented approach in discussions of specific research topics provides a stimulating and, hopefully, forward-looking volume which serves to update selected aspects of cancer research today. This combination will be useful to both the beginner as well as the more advanced biomedical scientist.

One of the main causes of failure in the treatment of breast cancer is the intrinsic presence of, or development of, drug resistance by the cancer cells. Recent studies on the mechanisms of cancer drug resistance have yielded important information highlighting both how tumour cells may escape these therapeutic constraints and that drug resistance may further impinge on tumour cell functions that may ultimately promote an adverse cell phenotype. New targets have been identified with potential therapeutic applications in resistant breast cancer leading to the subsequent evaluation of inhibitors of these targets in preclinical studies. Importantly, there is increasing evidence from such studies demonstrating the benefit of novel combination strategies as potential avenues for future drug regimens.

Written by experts in the subject area, this book covers the molecular details and functional consequences of endocrine resistance in breast cancer with particular emphasis on the future applications of novel drug combinations that may be utilized to circumvent resistance and improve anti-tumour effects. This book represents a timely publication in the field of breast cancer research, providing current knowledge in the area of drug resistance and will be important reading material for clinicians and researchers alike.

Inappropriate activation of the Wnt signaling pathway is observed in many human cancers and is sufficient to drive tumor initiation and progression in numerous contexts. Multiple mechanisms, such as overexpression of Wnt ligands, inactivation of the APC and Axin tumor suppressors, and mutation of -catenin, are responsible for pathway activation in tumor cells. The development of potent Wnt pathway antagonists for therapeutic use has been a major effort for investigators in both academia and industry in recent years. This book will provide an overview of the Wnt pathway as a therapeutic target for cancer, and discuss the preclinical development of inhibitors specifically directed to upstream and downstream components of the pathway.

Humans are diurnal organisms whose biological clock and temporal organization depend on natural light/dark cycles. Changes in the photoperiod are a signal for seasonal acclimatization of physiological and immune systems as well as behavioral patterns. The invention of electrical light bulbs created more opportunities for work and leisure. However, exposure to artificial light at night (LAN) affects our biological clock, and suppresses pineal melatonin (MLT) production. Among its other properties, MLT is an antioncogenic agent, and therefore its suppression increases the risks of developing breast and prostate cancers (BC&PC). To the best of our knowledge, this book is the first to address the linkage between light pollution and BC&PC in humans. It explains several state-of-the-art theories, linking light pollution with BC&PC. It also illustrates research hypotheses about health effects of light pollution using the results of animal models and population-based studies.

This volume of Molecular Biology of Hematopoiesis is dedicated to many inter national scientists and clinicians for their contribution to the field of Hematology/ Oncology presented at the 11th International Symposium on Molecular Biology of Hematopoiesis, which was held in Bormio, Italy, June 25-29, 1998. The continuous support of the Presidents of the meeting, Professor F. Takaku, President of Jichi University, and E. D. Thomas, Nobel Laureate, was greatly acknowledged, especially Professor Takaku, for his vision and support for development of gene therapy in Japan. New information on BMT for autoimmune disease and organ transplantation was presented at the symposium and is published in this volume. Several new findings on gene therapy/transfer into HSC were presented by E. F. Vanin and A. Nienhuis, K. Humphries, 1. A. Nolta, H. E. Heslop, and M. K. Brenner. Professors S. Asano and K. Tani presented new studies on gene transfer into primates. Among the highlights were the new papers on gene transfer presented by G. Wage maker, N. G. Abraham, and M. Onoderea from R. M. BJaese's group. The use of BMT for organ transplant and autoim mune disease was updated and a representative paper is presented in this volume.

The field of pediatric oncology encompasses four groups of malignancies - acute leukemias, brain tumors, lymphomas and solid tumors. 1'he history, diagnosis and management of children with acute leukemias and lymphomas has been thoroughly examined in several excellent textbooks of pediatric hematology and oncology. Bl"ain tumors have historically been managed by neurosurgeons and radiation therapists. 1'he role of the pediatric oncologist in the management of these patients is evolving. This book was written to provide a thorough historical evaluation of the most frequent solid tumors of children. A detailed examination of the natural history of these tumors is essential to the design and evaluation of therapeutic trials. The highly lethal nature of many of these tumors, the occurrence of some of them at several different primary sites and the rarity of these tumors have made systematic study of them difficult. Conclusions regarding the efficacy of a particular modification of the therapeutic strategy can be strongly influenced by the assumed natural history of the tumor. I have tried to develop as accurateJy as the literature would allow a picture of the natural history of the common malignant solid tumors, knowing that the image would be imperfect. I adopted a convention which was employed in all graphs constructeil from case reports summarized from the literature.

In 2000 the Department of Health issued a number of initiatives, with improving cancer treatment and research, and providing greater resources for cancer care being made a priority. Nurses and their colleague will be at the forefront of these changes.
The book presents specialized biological information on what cancer is, how it damages the body, and how cancer treatments work. Engaging, accessible and illustrated throughout, this unique text:
*explains the basic biology of cancer
*discusses the biology of wide range of common cancers
*identifies and explains the biological causes of cancer
*explains drug action in chemotherapy and analgesia
*explains the link between diet and cancer, and how diet is important in cancer therapy
*discusses the biological basis of a range of nursing skills linked to cancer.
This book will provide nurses with the essential knowledge required for working with cancer patient and their families, and will enable them to work with current and new forms of cancer treatment. It will also be of great use to clinical staff and nurse educators.

Image synthesis across and within medical imaging modalities is an active area of research with broad applications in radiology and radiation oncology. This book covers the principles and methods of medical image synthesis, along with state-of-the-art research. First, various traditional non-learning-based, traditional machine-learning-based, and recent deep-learning-based medical image synthesis methods are reviewed. Second, specific applications of different inter- and intra-modality image synthesis tasks and of synthetic image-aided segmentation and registration are introduced and summarized, listing and highlighting the proposed methods, study designs, and reported performances with the related clinical applications of representative studies. Third, the clinical usages of medical image synthesis, such as treatment planning and image-guided adaptive radiotherapy, are discussed. Last, the limitations and current challenges of various medical synthesis applications are explored, along with future trends and potential solutions to solve these difficulties. The benefits of medical image synthesis have sparked growing interest in a number of advanced clinical applications, such as magnetic resonance imaging (MRI)-only radiation therapy treatment planning and positron emission tomography (PET)/MRI scanning. This book will be a comprehensive and exciting resource for undergraduates, graduates, researchers, and practitioners.

Blood Cell Biochemistry was initially conceived as part of the Plenum series Subcellular Biochemistry, from which it has developed into a separate series. The present volume is devoted primarily to contributions on megakaryocytes and platelets and, to a lesser extent, to macrophages and eosinophils. The book does not attempt a rigorous or total coverage of the particular topics; it represents the areas of current scientific activity and interest that were selected by the editor at the commencement of this project. In general, the approach has been similar to that adopted for Volume 1 of the series (Erythroid Cells); the same approach will be followed subsequently in Volume 3 (Lymphocytes and Granulocytes). This book opens with a developmentally oriented chapter by Janine Breton-Gorius on megakaryocyte maturation and platelet release in normal conditions, which serves to set the scene ultrastructurally for much of the data that follow. The biosynthesis and process ing of platelet glycoproteins in megakaryocytes is dealt with by Alain Duperray and his colleagues, and thereby provides an in-depth biochemical survey of the megakaryocyte. The applications and strengths of crossed immunoelectrophoresis for the study of platelet membrane proteins is then covered by Simon Karpatkin, and a detailed account of the heredity disorders of platelet function is provided by Francine Rendu and Evelyne Dupuy."

This volume explores the myriad of techniques and methodological approaches that are being used in breast cancer research. The authors critically evaluate of the advantages and disadvantages of current methodologies, starting with the tools available for understanding the architecture of the human breast, including its tissue and cellular composition. The volume discusses the importance of functional studies in breast cancer research, especially with the help of laser capture microdissection, which allows the separation of small amounts of tissue, as well as specific cells, for biochemical analysis. In addition, the authors address methodologies including stem cell separation, which has helped in significantly understanding their role in normal breast development, but also further the understanding of breast cancer and its therapeutic management. The use of in vitro techniques and established cell lines for mechanistic studies in chemotherapeutic approaches have been invaluable will be discussed. Imaging techniques for evaluating in vitro and in vivo behavior of normal and cancerous breast tissue will be explored, as it provides a better understanding of the physiopathology of cancer. The volume will also discuss the molecular analysis of gene function in breast cancer through the transcriptomic and epigenomic profile. More importantly, the advancement of more refined techniques in sequencing will be covered. This monograph will be a comprehensive, authoritative and timely, as it addresses the emerging approaches used in breast cancer research.

Providing a true integration of pathology with clinical management, this volume presents a practical, comprehensive text on benign and malignant disease of the adult bladder. Integrating pathology, surgical management, oncology and molecular study in a site-specific manner to include the urethra, urinary bladder, ureter and renal pelvis, The Urinary Tract: A Comprehensive Guide to Patient Diagnosis and Management is the first text in adult bladder disease to closely interweave multiple clinical disciplines into each chapter. For the majority of chapters, a pathologist and urologist or urologic oncologist are paired to provide the greatest integration of information for each disease process.

Defining the Lung Cancer Problem 1 Lung cancer is the leading cause of cancer death in the world. It kills almost as many Americans as cancers of the breast, prostate, colon, rectum, pancreas, and 2 kidney combined, and accounts for 28.6% of all US cancer deaths. With an increase in the 5-year relative survival rate from 13% to only 16% in the more than 2 30 years from 1974 to the present, it will take us another 840 years to eradicate lung cancer deaths if we do not improve the current rate of progress. As discussed in this text, lung cancer prevention has received substantial att- tion. The decrease in smoking in recent decades has helped, but smoking is not the only problem. Lung cancer in people who have never smoked is currently the 5th 3 leading cause of cancer death in the United States. Several factors contribute to the lethality of lung cancer, including the rapidity of tumor growth, advanced stage at diagnosis (due to nonspecificity of early sy- toms and the uncertain efficacy of screening), early development of metastases, and resistance to therapy. Several chapters in this book discuss new molecular targets that may be potentially exploitable in the future, as well as discussing our track record to date in exploiting them.

This book presents in a comprehensive way cur the clinical care of the patient with head and neck rent advances in the management of neoplasia cancer involvement and/or its complications. and associated complications of the head and Today's complex treatments in oncology re neck. A broad range of clinical considerations is quire a comprehensive approach to effect a posi discussed following overviews of relevant basic tive result for the cancer patient whose facial biologic issues and the roles of various disci appearance and function are compromised. We plines. Each chapter has been structured to trust that physicians, dentists, nurses, dental "stand by itself"; at the same time, obvious rela hygienists, and individuals in the supportive ser tionships with other chapters have been noted. vices involved in the management of the cancer We are pleased that this book represents, in our patient will find this book beneficial. opinion, a truly multidisciplinary approach to Xl I. INTRODUCTION 1. CANCER, ITS COMPLICATIONS, AND THE HEAD AND NECK Stephen T. Sanis Few diseases are as complex in their biology, tumors, such as colorectal cancers, seems physiology, pathology, or management as can equivocal [3]. cer [1, 2]. In addition, the disease concurrently has extensive psychological impact on patients.

Historically, the field of hematopoietic growth factor research began with the work of Carnot and Deflandre-in 1906 they suggested that the rate of erythropoiesis is regulated by a humoral factor found in the blood, namely, erythropoietin. From this comparatively early start, accelerating progress has been made in erythropoietin research, which demon strates the general trends in this field of study. Erythropoietin was purified to homogeneity by 1977 (from enormous quantities of urine from aplastic anemia patients). Subsequently, the gene for erythropoietin has been cloned (1985), and massive quantities of this growth factor have been produced for clinical trials (late 1980s onward). Erythropoietin has become established as a pharmaceutical product of great value in the treatment of a number of diseases, most notably chronic renal failure. Once the ligand had been cloned, interest turned to the erythropoietin receptor, which was cloned in 1989. Since then, structure/ function studies have been performed on receptor mutants, cellular signaling events down stream from the occupied receptor have been identified, and the specific producer cell types and molecular stimuli for erythropoietin production have been thoroughly investigated, as has the regulation of erythropoietin gene transcription. This schedule of events since the 1970s typifies that seen for a number of hematopoietic growth factors. Along the way, the hematopoietic growth factors have been recognized as members of the cytokine family of signaling molecules that are important in a number of different physiological and patholog ical situations (see below)."

This monograph, written by well renowned breast cancer expect, Dr. Jose Russo, provides new insight on the pathobiology of breast cancer from the most current advances in the field, translational research, initiation and progression of the disease, the mechanism of invasion and metastasis and the concept of stem cells in treatment and drug resistance. The role of personalized medicine and genomic testing are also explored, which will provide a window to the future progress of cancer care.

Oncology has developed as a subspecialty of medicine with unique and often complex clinical problems. This handbook ofhematologic and oncologic emer gencies provides a compact, concise, yet comprehensive guide to the manage ment of a variety of difficult clinical situations. The authors of the various chapters are all clinicians with experience in the management of these difficult patients. Their efforts provide insight and a ready source of practical infor mation which lends itself to use in the clinic and in the inpatient ward. The authors sincerely hope that this handbook will be of service to house officers and fellows alike, as they develop skills in the management of the emergent problems of patients with hematologic and other neoplasms. Janice P. Dutcher Peter H. Wiernik Bronx, New York;; Contents 1. Syndrome of Inappropriate Antidiuretic Hormone Secretion and Hyponatremia . . . . . . . . . . . . . . . . . . . . . . . . 000 . . . . . . . . . . . Stuart L. Marcus, M.D., Ph.D., and Joachim Z. Fuks, M.D. 1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 2. Mechanisms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3. Etiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 4. Diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 5. Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 2. Acute Tumor Lysis Syndrome: Prevention and Management . . 9 Stuart L. Marcus, M.D., Ph.D., and Avi I. Einz;ig, M.D. 1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 2. Risk Factors for the Development of Azotemia in Acute Tumor Lysis Syndrome........................................... 10 3. Metabolic Abnormalities That Occur during Acute Tumor Lysis Syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 . . . . . . . . . . . . . . 4. Prevention of Acute Tumor Lysis Syndrome: Management prior to Beginning Chemotherapy . . . . . . . . . . . . . . . . . . . . . . . . . 13 . . . . . . . . . . 5. Posttreatment Management: Indications for Dialysis . . . . . . . . . . 14 . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 . . . . . . . . . . . . . ."